Market By Therapeutic Application, Product, Analysis Purpose, End-user, Analysis Platform, Biomarker Type, Clinical Application And Geography | Forecast 2019-2027
Triton’s research on the Europe liquid biopsy market depicts that it will grow at a stable pace with a CAGR of 21.97% in terms of revenue during the forecast period 2019-2027.
The countries that have been analyzed in the European liquid biopsy market are:
• The United Kingdom
• France
• Germany
• Italy
• Spain
• Russia
• Rest of Europe
Report scope can be customized per your requirements. Request For Customization
The usage of healthcare services in Europe is high among older individuals due to their susceptibility to diseases and infections. The trend analysis in this region points out that the per capita health expenditure on healthcare is higher among older people compared with other ages. In many western European countries, such as Ireland, Germany, Italy, the Netherlands and Denmark, point-of-care healthcare services and institutional long-term care services for older people are easily available. This helps the older people to opt for diagnostic tests (including biopsies) and treatments, taking care of factors such as ease of use, accessibility and affordability.
Numerous small-sized companies in the German market are developing potential liquid biopsy products. Acquisition of small companies by larger ones will increase the R&D investment, which can increase the product categories in the market. For instance, in May 2016, Siemens Healthineers acquired NEO New Oncology in Germany. The company is engaged in the development of NEOliquid, which a liquid biopsy test for analyzing the genomic profiles of solid tumours derived from simple blood samples. The acquisition helped Siemens Healthineers to enter the market and increase competitiveness.
I.M.S. Internazionale Medico Scientifica S.r.l. (IMS), is a medical device company that manufactures and distributes breast care devices, such as mammo diagnostics and biopsy imaging equipment. The company offers products such as tomosynthesis tomo or stereo biopsy, prone & upright mammography stereotactic and prone biopsy, digital mammography biopsy and prone, upright & lateral biopsy. It provides 3D imaging solutions. IMS collaborates with universities and hospital clinics for its research & development activities. The company markets its products through its authorized dealers. It has a presence in the US and Italy. IMS is headquartered in Sasso Marconi, Italy.
Market By Type, Application, E ..
VIEW REPORT
Market By Offerings, Technolog ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Test Types, Technolo ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT1.
EUROPE LIQUID BIOPSY MARKET - SUMMARY
2.
INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHT
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1.
THREAT OF NEW ENTRANTS
2.3.2.
THREAT OF SUBSTITUTES
2.3.3.
BARGAINING POWER OF BUYERS
2.3.4.
BARGAINING POWER OF SUPPLIERS
2.3.5.
THREAT OF RIVALRY
2.4. REGULATORY FRAMEWORK
2.5. KEY MARKET TRENDS
2.6. KEY LIQUID BIOPSY INITIATIVES
2.7. MARKET ATTRACTIVENESS INDEX
2.8. MARKET DRIVERS
2.8.1.
CANCER CASES IN OLDER POPULACE ARE SIGNIFICANTLY INCREASING
2.8.2.
DIAGNOSTIC CENTERS ARE IN DEMAND
2.8.3.
TISSUE/TUMOR-AGNOSTIC DRUGS USAGE ARE INCREASING
2.8.4.
RISE IN USAGE OF PRECISION MEDICINE
2.9. MARKET RESTRAINTS
2.9.1.
HIGH COST OF TEST
2.9.2.
LACK OF A CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPs)
2.10.
MARKET OPPORTUNITIES
2.10.1.
ADVANCEMENT IN TECHNOLOGY
2.10.2.
RISING NUMBER OF CANCER PATIENTS
2.11.
MARKET CHALLENGES
2.11.1.
LACK OF REIMBURSEMENT
2.11.2.
SKILLED PROFESSIONALS ARE QUITE LESS IN NUMBER
3.
LIQUID BIOPSY MARKET OUTLOOK - BY THERAPEUTIC APPLICATION
3.1. PROSTATE CANCER
3.2. MELANOMA CANCER
3.3. BREAST CANCER
3.4. COLORECTAL CANCER
3.5. LUNG CANCER
3.6. OTHER TYPES OF CANCER
3.7. NON-ONCOLOGY APPLICATIONS
4.
LIQUID BIOPSY MARKET OUTLOOK - BY PRODUCT
4.1. CELL-FREE DNA (CFDNA)
4.2. CIRCULATING TUMOR CELLS (CTCS)
4.3. CIRCULATING TUMOR DNA (CTDNA)
4.4. EXTRACELLULAR VESICLES AND OTHERS
5.
LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PURPOSE
5.1. MONITORING
5.2. THERAPY GUIDANCE
5.3. EARLY DETECTION/SCREENING
5.4. DIAGNOSIS
6.
LIQUID BIOPSY MARKET OUTLOOK - BY END-USER
6.1. HOSPITALS
6.2. PHYSICIANS’ OFFICE LABORATORIES
6.3. CLINICAL DIAGNOSTIC LABORATORIES
7.
LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PLATFORM
7.1. MICROARRAY
7.2. NGS
7.3. PROTEOMICS
7.4. PCR
7.5. OTHER ANALYSIS PLATFORMS
8.
LIQUID BIOPSY MARKET OUTLOOK - BY BIOMARKER TYPE
8.1. NUCLEIC ACIDS
8.2. PROTEINS
8.3. EXTRACELLULAR VESICLES
8.4. CELLS
9.
LIQUID BIOPSY MARKET OUTLOOK - BY CLINICAL APPLICATION
9.1. TREATMENT MONITORING
9.2. PROGNOSIS & REOCCURRENCE MONITORING
9.3. TREATMENT SELECTION
9.4. DIAGNOSIS & SCREENING
10. LIQUID BIOPSY MARKET - REGIONAL OUTLOOK
10.1.
EUROPE
10.2.
COUNTRY ANALYSIS
10.2.1.1.
THE UNITED KINGDOM
10.2.1.2.
FRANCE
10.2.1.3.
GERMANY
10.2.1.4.
ITALY
10.2.1.5.
SPAIN
10.2.1.6.
RUSSIA
10.2.1.7.
REST OF EUROPE
11. COMPETITIVE LANDSCAPE
11.1.
AGILENT TECHNOLOGIES, INC.
11.2.
BOSTON SCIENTIFIC CORPORATION
11.3.
ARGON MEDICAL DEVICES, INC.
11.4.
B. BRAUN MELSUNGEN AG
11.5.
CINTEC MEDICAL LTD.
11.6.
ROCHE DIAGNOSTICS CORPORATION
11.7.
AD-TECH MEDICAL INSTRUMENT CORP.
11.8.
I.M.S. INTERNAZIONALE MEDICO SCIENTIFICA SRL
11.9.
QIAGEN N.V.
11.10.
BECTON, DICKINSON
11.11.
PLANMECA OY
11.12.
BIO-RAD LABORATORIES, INC.
11.13.
CARDINAL HEALTH, INC.
11.14.
COOK MEDICAL, INC.
11.15.
FISCHER MEDICAL TECHNOLOGIES LLC
11.16.
C. R. BARD, INC. (ACQUIRED BY BECTON, DICKINSON AND COMPANY)
12. RESEARCH METHODOLOGY & SCOPE
12.1.
RESEARCH SCOPE & DELIVERABLES
12.1.1.
OBJECTIVES OF STUDY
12.1.2.
SCOPE OF STUDY
12.2.
SOURCES OF DATA
12.2.1.
PRIMARY DATA SOURCES
12.2.2.
SECONDARY DATA SOURCES
12.3.
RESEARCH METHODOLOGY
12.3.1.
EVALUATION OF PROPOSED MARKET
12.3.2.
IDENTIFICATION OF DATA SOURCES
12.3.3.
ASSESSMENT OF MARKET DETERMINANTS
12.3.4.
DATA COLLECTION
12.3.5.
DATA VALIDATION & ANALYSIS
TABLE 1 EUROPE LIQUID BIOPSY
MARKET 2019-2027 ($ MILLION)
TABLE 2 LIQUID BIOPSY
BIOMARKER CLASSES
TABLE 3 EUROPE LIQUID BIOPSY
MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 4 EUROPE LIQUID BIOPSY
MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 5 EUROPE LIQUID BIOPSY
MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 6 EUROPE LIQUID BIOPSY
MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 7 EUROPE LIQUID BIOPSY
MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 8 ADVANTAGES OF
DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
TABLE 9 DROPLET DIGITAL PCR
INDUSTRIES
TABLE 10 EUROPE LIQUID BIOPSY
MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 11 CELL DIFFERENTIATORS
TABLE 12 EUROPE LIQUID BIOPSY
MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 13 EUROPE LIQUID BIOPSY
MARKET BY COUNTRY 2019-2027 ($ MILLION)
FIGURE 1 EUROPE LIQUID BIOPSY
MARKET 2019-2027 ($ MILLION)
FIGURE 2 EUROPE LIQUID BIOPSY
MARKET BY PROSTATE CANCER 2019-2027 ($ MILLION)
FIGURE 3 EUROPE LIQUID BIOPSY
MARKET BY MELANOMA CANCER 2019-2027 ($ MILLION)
FIGURE 4 TYPES OF BREAST
CANCER
FIGURE 5 EUROPE LIQUID BIOPSY
MARKET BY BREAST CANCER 2019-2027 ($ MILLION)
FIGURE 6 EUROPE LIQUID BIOPSY
MARKET BY COLORECTAL CANCER 2019-2027 ($ MILLION)
FIGURE 7 EUROPE LIQUID BIOPSY
MARKET BY LUNG CANCER 2019-2027 ($ MILLION)
FIGURE 8 EUROPE LIQUID BIOPSY
MARKET BY OTHER TYPES OF CANCER 2019-2027 ($ MILLION)
FIGURE 9 EUROPE LIQUID BIOPSY
MARKET BY NON-ONCOLOGY APPLICATION 2019-2027 ($ MILLION)
FIGURE 10 EUROPE LIQUID BIOPSY
MARKET BY CELL-FREE DNA (CFDNA) 2019-2027 ($ MILLION)
FIGURE 11 EUROPE LIQUID BIOPSY
MARKET BY CIRCULATING TUMOR CELLS (CTCS) 2019-2027 ($ MILLION)
FIGURE 12 EUROPE LIQUID BIOPSY
MARKET BY CIRCULATING TUMOR DNA (CTDNA) 2019-2027 ($ MILLION)
FIGURE 13 EUROPE LIQUID BIOPSY
MARKET BY EXTRACELLULAR VESICLES AND OTHERS 2019-2027 ($ MILLION)
FIGURE 14 EUROPE LIQUID BIOPSY
MARKET BY MONITORING 2019-2027 ($ MILLION)
FIGURE 15 EUROPE LIQUID BIOPSY
MARKET BY THERAPY GUIDANCE 2019-2027 ($ MILLION)
FIGURE 16 EUROPE LIQUID BIOPSY
MARKET BY EARLY DETECTION/SCREENING 2019-2027 ($ MILLION)
FIGURE 17 EUROPE LIQUID BIOPSY
MARKET BY DIAGNOSIS 2019-2027 ($ MILLION)
FIGURE 18 EUROPE LIQUID BIOPSY
MARKET BY HOSPITALS 2019-2027 ($ MILLION)
FIGURE 19 EUROPE LIQUID BIOPSY
MARKET BY PHYSICIANS’ OFFICE LABORATORIES 2019-2027 ($ MILLION)
FIGURE 20 EUROPE LIQUID BIOPSY
MARKET BY CLINICAL DIAGNOSTIC LABORATORIES 2019-2027 ($ MILLION)
FIGURE 21 EUROPE LIQUID BIOPSY
MARKET BY MICROARRAY 2019-2027 ($ MILLION)
FIGURE 22 EUROPE LIQUID BIOPSY
MARKET BY NGS 2019-2027 ($ MILLION)
FIGURE 23 EUROPE LIQUID BIOPSY
MARKET BY PROTEOMICS 2019-2027 ($ MILLION)
FIGURE 24 EUROPE LIQUID BIOPSY
MARKET BY PCR 2019-2027 ($ MILLION)
FIGURE 25 EUROPE LIQUID BIOPSY
MARKET BY OTHER ANALYSIS PLATFORM 2019-2027 ($ MILLION)
FIGURE 26 EUROPE LIQUID BIOPSY
MARKET BY NUCLEIC ACIDS 2019-2027 ($ MILLION)
FIGURE 27 EUROPE LIQUID BIOPSY
MARKET BY PROTEINS 2019-2027 ($ MILLION)
FIGURE 28 EUROPE LIQUID BIOPSY
MARKET BY EXTRACELLULAR VESICLES 2019-2027 ($ MILLION)
FIGURE 29 EUROPE LIQUID BIOPSY
MARKET BY CELLS 2019-2027 ($ MILLION)
FIGURE 30 EUROPE LIQUID BIOPSY
MARKET BY TREATMENT MONITORING 2019-2027 ($ MILLION)
FIGURE 31 EUROPE LIQUID BIOPSY
MARKET BY PROGNOSIS & REOCCURRENCE MONITORING 2019-2027 ($ MILLION)
FIGURE 32 EUROPE LIQUID BIOPSY
MARKET BY TREATMENT SELECTION 2019-2027 ($ MILLION)
FIGURE 33 EUROPE LIQUID BIOPSY
MARKET BY DIAGNOSIS & SCREENING 2019-2027 ($ MILLION)
FIGURE 34 THE UNITED KINGDOM
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 35 FRANCE LIQUID BIOPSY
MARKET 2019-2027 ($ MILLION)
FIGURE 36 GERMANY LIQUID BIOPSY
MARKET 2019-2027 ($ MILLION)
FIGURE 37 ITALY LIQUID BIOPSY
MARKET 2019-2027 ($ MILLION)
FIGURE 38 SPAIN LIQUID BIOPSY
MARKET 2019-2027 ($ MILLION)
FIGURE 39 RUSSIA LIQUID BIOPSY
MARKET 2019-2027 ($ MILLION)
FIGURE 40 REST OF EUROPE LIQUID
BIOPSY MARKET 2019-2027 ($ MILLION)